ArticleCureus2024
An Intriguing Case of Delirium: Recognizing Steroid-Responsive Encephalopathy Associated With Autoimmune Thyroiditis.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Research progress on the association between Hashimoto's thyroiditis and autoimmune encephalitis: a review.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Steroid-responsive encephalopathy, also known as Hashimoto's encephalopathy, is an uncommon autoimmune neuroendocrine disorder linked to thyroiditis. It presents a variable range of clinical symptoms, making it challenging to diagnose. SREAT (steroid-responsive encephalopathy associated with autoimmune thyroiditis) is considered a diagnosis of exclusion. Diagnosing SREAT poses a challenge as its symptoms can overlap with those of acute conditions such as encephalitis and meningitis, as well as various autoimmune disorders and issues related to substance toxicity and abuse, all of which must be ruled out prior to establishing a definitive diagnosis and starting treatment. However, high anti-TPO antibodies (anti-thyroid peroxidase) in serum and rarely in the CSF favor the diagnosis of the condition. Although rare, Hashimoto's encephalopathy should be considered when managing cases of unexplained encephalopathy. Treatment of choice in these sets of patients includes high-dose corticosteroid therapy. We present a case of Hashimoto's encephalopathy in a middle-aged woman who arrived at our emergency department with altered mental status and facio-brachial seizures. After excluding various potential causes of acute encephalopathy, a diagnosis of SREAT was made. Testing of serum and cerebrospinal fluid (CSF) indicated the presence of anti-thyroid peroxidase (anti-TPO) antibodies, which is uncommon in CSF. Following intravenous steroid therapy, the patient experienced substantial improvement, reinforcing the diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.